The US Prescription Drug User Fee Act goal date for albiglutide is now set for April 15th 2014. This provides extra time for a full review of information submitted by GSK in response to the FDA's ...

GlaxoSmithKline is in a spree of producing new diabetes and cancer drugs which it hopes will increase its sales this year. After the recent U.S. drug approvals it is starting to market two of its ...

The furore over Avandia (rosiglitazone), GlaxoSmithKline's blockbuster drug for diabetes, illustrates how much the US drug business has changed over the past 3 years. Safety concerns over Avandia ...

It's a very busy and spooky Halloween eve today — several companies had big misses in earnings reported this morning. Let's ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

In April, NICE’s appraisal committee issued a ‘not recommended’ draft decision on the drug, ruling that the evidence presented by GSK suggested ... such as diabetes, high blood pressure ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Rosiglitazone, the diabetes drug taken by up to 100,000 people in the UK has been ... which was released to the market 10 years ago for people with type 2 diabetes. GlaxoSmithKline, which produces ...

New Delhi: GlaxoSmithKline's antibiotic drug Augmentin has risen to the top slot in the Indian pharmaceutical market, pushing the popular anti-diabetes drug Glycomet GP to the second slot.

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...

The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...